SEPSECS

Across TCGA pan-cancer cohorts, SEPSECS mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SEPSECS data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SEPSECS mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SEPSECS expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and GBM are the cancer types where SEPSECS mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	III,IV	0.647	0.200	<.001	61	view →
CCRCC	DFS	Quartile	III,IV	0.897	0.258	<.001	59	view →
GBM	OS	Quartile	All	0.342	0.662	<.001	23	view →
LUAD	OS	Tertile	All	0.945	0.799	.019	9	view →
LSCC	DFS	Quartile	II,III,IV	0.250	0.887	.024	4	view →
HNSC	DFS	Median	IV	1.000	0.927	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SEPSECS–PDAC (OS)

Open the PDAC breakdown →